OncoMatch/Clinical Trials/NCT06128551
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Is NCT06128551 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Elironrasib and Daraxonrasib for non-small cell lung cancer (nsclc).
Treatment: Elironrasib · Daraxonrasib — This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Pancreatic Cancer
Biomarker criteria
Required: KRAS g12c
Disease stage
Metastatic disease required
advanced or metastatic solid tumors not amendable to curative therapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immunotherapy — NSCLC, dose expansion/phase 2
NSCLC, previously treated with immunotherapy
Must have received: chemotherapy — NSCLC, dose expansion/phase 2
NSCLC, previously treated with chemotherapy
Must have received: KRAS inhibitor — NSCLC, dose expansion/phase 2
NSCLC, previously treated with KRAS G12C (OFF) inhibitors
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- UC IRVINE Health · Orange, California
- UC Davis Comprehensive Cancer Center · Sacramento, California
- Stanford Cancer Institute · Stanford, California
- University of Colorado Cancer Center · Aurora, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify